[The serum concentration of interleukin-2 in a hemodialysis patient--report from interleukin adjuvant therapy for local recurrent renal cancer].
We started interleukin-2 (IL-2) adjuvant therapy after resection of a repeated local recurrence of renal cell carcinoma in a hemodialysis patient. It is reported that IL-2 is mainly metabolized in proximal tubules of the kidney. To determine the IL-2 concentration, we employed the ELISA method using anti-human IL-2 antibodies. At the concentration of 350,000 Japan reference unit (JRU) in a hemodialysis patient, the change in serum IL-2 was almost the same speed compared to 700,000 JRU in normal renal function patients, which was reported previously. This report may also be a good tool to define the ideal dose of IL-2 in hemodialysis patients.
Ishizuka
Osamu
O
Dept. of Urology, Shinshu University School of Medicine.
Tanabe
Tomoaki
T
Nakayama
Tsuyoshi
T
Kinebuchi
Yoshiaki
Y
Ogawa
Teruyuki
T
Nishizawa
Osamu
O
D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage*; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000628:therapy; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy; D006435:Renal Dialysis
D000277:Adjuvants, Pharmaceutic; D000970:Antineoplastic Agents; D007376:Interleukin-2